B+
Bull case
20%
Probability
Target price
$0.90
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
JAGX
Jaguar HealthBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$0.38
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.12
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-04-17
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+72.5
Score
AI commentary
Sentiment is best framed as cautious monitoring, not a clean bullish setup. The April 2026 8-K removed some immediate balance-sheet pressure by asserting restored equity above Nasdaq's minimum, but the 10-K still carries going-concern language and the equity story remains dependent on follow-through cash receipts and speculative rare-disease trial progress [#8-K-2026-04-09][#10-K-2026-04-07].
RankAlpha Sentiment Codex - 2026-04-17
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30eventFuture Pak post-closing cash receipts and initial product sales need to convert from promise to cashHigh impact
Primary sources point to a remaining $2 million payment upon completion of post-closing conditions, approximately $1.2 million from a firm Mytesi product order, and additional commercialization-linked payments under the January 12, 2026 licensing arrangement. Receipt timing matters because the 10-K still says the company lacks sufficient cash resources to fund operations through March 2027 [#8-K-2026-04-09][#10-K-2026-04-07][#PR-2026-01-12].
2026-06-30catalystNasdaq equity compliance remains a live near-term swing factorHigh impact
The April 9, 2026 8-K says Jaguar had an approximately $18.7 million stockholders' deficit at December 31, 2025, but believes stockholders' equity exceeded the Nasdaq $2.5 million minimum by April 7, 2026 after the January licensing deal, related cash receipts, expected post-closing proceeds, inventory sales, grant revenue, and debt extinguishment. Confirmation that Nasdaq accepts this recovery would ease an acute overhang; failure would keep listing risk front and center [#8-K-2026-04-09].
2026-06-30catalystMVID Phase 2 completion is the only clear operating upside hook, but it is still highly speculativeHigh impact
Jaguar said on January 22, 2026 that its placebo-controlled Phase 2 trial of crofelemer in pediatric MVID is expected to complete in Q2 2026, and that positive results plus the amended protocol could support a faster FDA path and possible Breakthrough Therapy and EMA PRIME discussions. This is the main program-level upside driver, but it remains contingent on small-study clinical execution and favorable data [#PR-2026-01-22][#PR-2026-01-12].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-17 • Updated nightlySource: Internal modelMethodology